News Details
NCCN Collaborates with Pfizer to Improve Provider Performance and Quality in Treatment of Metastatic Breast Cancer
NCCN and Pfizer will elicit grant proposals for quality improvement and education in metastatic breast cancer.
FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) is collaborating with Pfizer Independent Grants for Learning & Change (IGLC) to establish a peer-reviewed grant program to elicit proposals focused on health care provider performance and/or health care quality improvement and education projects. As part of this program, the NCCN ORP and Pfizer will jointly issue a Request for Proposals (RFP), focused on the development and adoption of evidence-based initiatives to improve patient care and outcomes in metastatic breast cancer.
The intent of the RFP is to encourage academic and community-based organizations to submit proposals describing concepts and ideas for design and implementation of programs that address clinical practice gaps and improve the care of patients through increased competence and performance of health care providers and health care systems. It is expected to fund approximately six to eight projects.
“Through this collaboration, NCCN and Pfizer IGLC strive to improve the lives of people with cancer through the advancement of evidence-based treatment recommendations in tandem with enhanced clinician education and supportive care services,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “NCCN is grateful for the opportunity to work with Pfizer on this important initiative.”
The NCCN ORP and Pfizer will announce an RFP seeking concepts for initiatives focusing on the following areas where gaps in care currently exist:
- Provider education and provider/patient treatment shared decision-making
- Adoption of evidence-based recommendations for management of metastatic breast cancer
- Information related to patient assistance programs and other patient-centered resources
- Comprehensive approaches to improving health care delivery systems
The NCCN ORP, organized to obtain funding to support scientifically meritorious research studies at NCCN Member Institutions, will be the lead organization for review and evaluation of applications. A review committee, led by NCCN and including a medical representative from Pfizer, will make decisions on which proposals will receive funding. Grant funding will be provided by Pfizer IGLC.
For more information about NCCN ORP and to view the RFP, visit NCCN.org. To view the RFP, visit http://www.nccn.org/clinical_trials/investigators/rfp/pfizer.aspx.
###